An iminosugar with potent inhibition of dengue virus infection in vivo

Antiviral Res. 2013 Apr;98(1):35-43. doi: 10.1016/j.antiviral.2013.01.004. Epub 2013 Jan 31.


The aim of the present study was to evaluate the ability of the iminosugar drug UV-4 to provide in vivo protection from lethal dengue virus (DENV) challenge. This study utilized a well-described model of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS)-like lethal disease in AG129 mice lacking the type I and II interferon receptors. Herein, we present UV-4 as a potent iminosugar for controlling DENV infection and disease in this mouse model. Specifically, administration of UV-4 reduced mortality, as well as viremia and viral RNA in key tissues, and cytokine storm. In addition, UV-4 treatment can be delayed, and it does not alter the anti-DENV antibody response. These results have set the foundation for development of UV-4 as a DENV-specific antiviral in phase I human clinical trials.

MeSH terms

  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Cytokines
  • Dengue / drug therapy*
  • Dengue / immunology
  • Dengue / virology*
  • Dengue Virus / drug effects*
  • Dengue Virus / physiology
  • Humans
  • Imino Sugars / chemistry
  • Imino Sugars / pharmacology*
  • Mice
  • Mice, Inbred Strains
  • Structure-Activity Relationship


  • Antiviral Agents
  • Cytokines
  • Imino Sugars